Ischemic cardiovascular disease in persons with human immunodeficiency virus infection

被引:70
作者
David, MH
Hornung, R
Fichtenbaum, CJ
机构
[1] Univ Cincinnati, Coll Med, Dept Med, Div Infect Dis,Holmes Div, Cincinnati, OH 45267 USA
[2] Univ Cincinnati, Coll Med, Inst Hlth Policy & Hlth Serv Res, Cincinnati, OH USA
[3] St Louis Univ, St Johns Mercy Med Ctr, St Louis, MO 63103 USA
关键词
D O I
10.1086/324745
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Persons with human immunodeficiency virus (HIV) infection might be at risk for ischemic cardiovascular disease (CVD). We reviewed the records of 16 HIV-infected persons with proven CVD (8 cases of angina and 8 cases of myocardial infarctions). This represents 1.7% of HIV-infected persons seen at our institution from 1 April 1999 through 25 April 2000. In comparison with 32 HIV-infected age- and sex-matched controls, case patients had more risk factors for CVD (median number of risk factors for CVD, 3 versus 1;), lower P < .001 nadir CD4(+) lymphocyte counts (median, 101 cells/mm(3) versus 278 cells/mm(3); P = .02), and a longer duration of prior exposure to nucleoside analogs (median, 190 weeks versus 130 weeks;P = .02). There was no difference in the duration of exposure to protease inhibitors. Ischemic CVD occurs in HIV-infected persons and appears to be most closely associated with traditional risk factors for coronary artery disease (for example, hypertension and hypercholesterolemia). Lower CD4(+) lymphocyte counts and duration of HIV infection might also be risk factors or markers for the development of ischemic CVD.
引用
收藏
页码:98 / 102
页数:5
相关论文
共 14 条
  • [1] Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study
    Carr, A
    Samaras, K
    Thorisdottir, A
    Kaufmann, GR
    Chisholm, DJ
    Cooper, DA
    [J]. LANCET, 1999, 353 (9170) : 2093 - 2099
  • [2] Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
    Carr, A
    Samaras, K
    Chisholm, DJ
    Cooper, DA
    [J]. LANCET, 1998, 351 (9119) : 1881 - 1883
  • [4] Primary prevention of coronary heart disease: Guidance from Framingham - A statement for healthcare professionals from the AHA task force on risk reduction
    Grundy, SM
    Balady, GJ
    Criqui, MH
    Fletcher, G
    Greenland, P
    Hiratzka, LF
    Houston-Miller, N
    Kris-Etherton, P
    Krumholz, HM
    LaRosa, J
    Ockene, IS
    Pearson, TA
    Reed, J
    Washington, R
    Smith, SC
    [J]. CIRCULATION, 1998, 97 (18) : 1876 - 1887
  • [5] GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015
  • [6] Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy
    Hadigan, C
    Meigs, JB
    Corcoran, C
    Rietschel, P
    Piecuch, S
    Basgoz, N
    Davis, B
    Sax, P
    Stanley, T
    Wilson, PWF
    D'Agostino, RB
    Grinspoon, S
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 32 (01) : 130 - 139
  • [7] Severe premature coronary artery disease with protease inhibitors
    Henry, K
    Melroe, H
    Huebsch, J
    Hermundson, J
    Levine, C
    Swensen, L
    Daley, J
    [J]. LANCET, 1998, 351 (9112) : 1328 - 1328
  • [8] MYOCARDITIS AND CARDIOTROPIC VIRAL-INFECTION ASSOCIATED WITH SEVERE LEFT-VENTRICULAR DYSFUNCTION IN LATE-STAGE INFECTION WITH HUMAN-IMMUNODEFICIENCY-VIRUS
    HERSKOWITZ, A
    WU, TC
    WILLOUGHBY, SB
    VLAHOV, D
    ANSARI, AA
    BESCHORNER, WE
    BAUGHMAN, KL
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 24 (04) : 1025 - 1032
  • [9] HIV protease inhibitors: Advances in therapy and adverse reactions, including metabolic complications
    Kaul, DR
    Cinti, SK
    Carver, PL
    Kazanjian, PH
    [J]. PHARMACOTHERAPY, 1999, 19 (03): : 281 - 298
  • [10] KLEIN D, 2001, 8 C RETR OPP INF CHI, P241